Plural Carbocyclic Rings Bonded Directly To The Same Acyclic Carbon Atom Which Is Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Patents (Class 514/255.04)
-
Publication number: 20090186099Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: January 9, 2009Publication date: July 23, 2009Inventor: Harry A. Dugger, III
-
Publication number: 20090175793Abstract: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.Type: ApplicationFiled: December 19, 2008Publication date: July 9, 2009Inventors: Alasdair Mark Naylor, Rachel Jane Russell, Stephen Derek Albert Street, Kim-Wah Tang, Pieter Hadewijn Van Der Graaf, Christopher Peter Wayman
-
Publication number: 20090176792Abstract: The present invention relates to new dibenzhydrylpiperazine modulators of histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: January 7, 2009Publication date: July 9, 2009Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20090175950Abstract: Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided.Type: ApplicationFiled: March 16, 2009Publication date: July 9, 2009Inventor: Richard H. Roberts
-
Publication number: 20090175941Abstract: The invention describes a pharmaceutical composition of a slow-release preparation in the form of tablets for the treatment of vertigo of any genesis. A pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down. For this purpose, the pharmaceutical composition additionally contains binding agent, slow-release agent and fillers.Type: ApplicationFiled: March 23, 2006Publication date: July 9, 2009Inventor: Gernot Francas
-
Publication number: 20090176804Abstract: The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.Type: ApplicationFiled: January 22, 2009Publication date: July 9, 2009Inventors: Zhaoxia YANG, Stephan REILING, Thaddeus NIEDUZAK, Rose M. MATHEW, Sharon JACKSON, Keith John HARRIS
-
Patent number: 7538114Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: GrantFiled: June 26, 2007Date of Patent: May 26, 2009Assignee: Amgen Inc.Inventors: Stephen Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
-
Publication number: 20090131433Abstract: This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-iType: ApplicationFiled: June 12, 2006Publication date: May 21, 2009Applicant: PFIZER INC.Inventor: Travis T. Wager
-
Patent number: 7531543Abstract: The present invention is directed to phenylpiperazine cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.Type: GrantFiled: October 12, 2004Date of Patent: May 12, 2009Assignee: WyethInventors: Paige Erin Mahaney, Eugene John Trybulski, Lori Krim Gavrin, An Thien Vu
-
Publication number: 20090111833Abstract: Methods of treating or preventing a vertigo, nausea, or vomiting condition comprising injecting a subject with a pharmaceutically acceptable formulation consisting essentially of an effective amount of meclizine or a pharmaceutically acceptable salt thereof, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 are disclosed. An injectable pharmaceutical formulation for treating or preventing a vertigo, nausea, or vomiting condition consisting essentially of an effective amount of meclizine, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 is also disclosed.Type: ApplicationFiled: October 31, 2007Publication date: April 30, 2009Inventors: Walker Anderson LONG, Edwin Curran MURPHY, III
-
Publication number: 20090105276Abstract: The present invention is directed to methods of treatment for scabies using different concentrations of lindane lotions for varying contact times. Compositions of low concentration lindane lotions are also included.Type: ApplicationFiled: February 15, 2008Publication date: April 23, 2009Inventor: Brian TAMBI
-
Publication number: 20090082364Abstract: The present application describes deuterium-enriched levocetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090075960Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.Type: ApplicationFiled: August 22, 2008Publication date: March 19, 2009Applicants: THE HOSPITAL FOR SICK CHILDREN, McMASTER UNIVERSITYInventors: Don J. Mahuran, Michael B. Tropak, Justin D. Buttner, Jan E. Blanchard, Eric D. Brown
-
Publication number: 20090069290Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.Type: ApplicationFiled: October 30, 2008Publication date: March 12, 2009Inventors: Peter Werner, David Pitt, Elimor Brand-Schieber
-
Publication number: 20090062305Abstract: The present application describes deuterium-enriched cetirizine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 21, 2008Publication date: March 5, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Patent number: 7498334Abstract: Pyrrolopyrimidine derivatives of the formula I in which R3, R4, R5, R6 and X are as defined in claim 1, act as phosphodiesterase VII inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.Type: GrantFiled: November 8, 2002Date of Patent: March 3, 2009Assignee: Merck Patent GmbHInventors: Hans-Michael Eggenweiler, Michael Wolf
-
Publication number: 20090048268Abstract: The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less than about 0.2%. The storage stable solution preferably contains cetirizine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid solution as well as a method of treating a mammal with a therapeutically effective amount of cetirizine in the stable pharmaceutical liquid solution.Type: ApplicationFiled: January 25, 2007Publication date: February 19, 2009Applicant: Taro Pharmaceuticals North America, Inc.Inventors: Satish Asotra, Jerzy Zadykowicz, Kalpana Vanam, Shen Gao
-
Publication number: 20090047343Abstract: The present invention relates to a process for stabilizing phenylephrine including drying an acidic solution of phenylephrine and pharmaceutical compositions including stabilized phenylephrine.Type: ApplicationFiled: August 13, 2007Publication date: February 19, 2009Inventors: Hugh Huang, Jonathan Zeszotarski, Anthony Bean, William Michael Nichols
-
Publication number: 20090047344Abstract: The present invention relates to pharmaceutical compositions for oral administration of active compounds.Type: ApplicationFiled: August 28, 2008Publication date: February 19, 2009Inventors: Domenico Fanara, Monique Berwaer, Anthony Guichaux, Michel Deleers
-
Publication number: 20090042861Abstract: The present invention provides a prophylactic or therapeutic agent for depression or anxiety disorders, comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.Type: ApplicationFiled: April 3, 2006Publication date: February 12, 2009Applicant: Takeda Pharmaceutical Company LimitedInventors: Keisuke Hirai, Masaomi Miyamoto
-
Publication number: 20090036469Abstract: The present invention is directed to a compound of formula (I), wherein R1 and R2 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder by administering to said patient a pharmaceutically effective amount of a compound of the invention.Type: ApplicationFiled: October 7, 2008Publication date: February 5, 2009Applicant: SANOFI-AVENTISInventors: David STEFANY, Keith John HARRIS, Timothy Alan GILLESPY, Charles J. GARDNER, Joacy C. AGUIAR
-
Publication number: 20080312168Abstract: The present invention relates to a novel dispersible tablet composition, which comprises of a pharmacologically active ingredient and at least one excipient, which reduces the sedimentation rate of active ingredient. This invention further relates to a process for the preparation of a dispersible tablet of a pharmacologically active ingredient.Type: ApplicationFiled: July 24, 2006Publication date: December 18, 2008Applicant: RUBICON RESEARCH PVT. LTDInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Pradnya Bagde, Varsha Barve
-
Publication number: 20080306090Abstract: Thiourea compounds of the following formula: wherein n, R1, R2, R3, A1, A2, X, Y, and Z are defined herein. Also disclosed is a method of treating hepatitis C virus infection with these compounds.Type: ApplicationFiled: May 5, 2008Publication date: December 11, 2008Applicant: National Health Research InstitutesInventors: Jyh-Haur Chern, Tsu-An Hsu, Iou-Jiun Kang, Li-Wen Wang, Chung-Chi Lee, Yen-Chun Lee, Yu-Sheng Chao
-
Publication number: 20080300262Abstract: The present invention relates to analgesic compositions comprising a non-peptidyl N-type calcium channel blocker, and at least one other analgesic compound, and to methods of using N-type calcium channel blockers in combination with at least one other pain-relieving compound that alleviates pain through a mechanism other than N-type calcium channel blockage, or with a non-pharmacological therapeutic protocol.Type: ApplicationFiled: April 10, 2006Publication date: December 4, 2008Inventor: Terrance P. Snutch
-
Publication number: 20080287456Abstract: The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system.Type: ApplicationFiled: May 27, 2005Publication date: November 20, 2008Applicant: IMAGINOT PTY LTDInventors: Michael Stephen Roberts, Ruoying Jiang, Keivan Bezanehtak, Greg Davey, George Alexander Davidson, Geraldine Ann Elliott, Stephen Douglas Chandler, Mantu Sarkar
-
Publication number: 20080287459Abstract: The present invention is related to an orally administered pharmaceutical composition for the prevention of hair loss; having the effects of epilation, hair toning, and hair growth; and for the treatment of female hirsutism and benign prostatic hyperplasia. The composition of the present invention is non-steroidal and is advantageous in that it has no side effects such as lowering of sexual function, etc. shown in the conventional oral treatment agents of related diseases.Type: ApplicationFiled: April 13, 2005Publication date: November 20, 2008Inventor: Eun-Joo Lee
-
Publication number: 20080275015Abstract: The invention of this application relates to a formulation and method of using the formulation for the treatment of interstitial cystitis and other similar conditions of the bladder. The formulation of this invention is a highly specialized, compounded pharmaceutical that contains a combination of numerous therapeutically different medications in a unique delivery vehicle and system. The individual components of the formulation work synergistically to restore and repair each of the different issues associated with interstitial cystitis. The individual components of the formulation exist in an aqueous vehicle to facilitate drug contact with the bladder wall. The formulation is instilled directly into the bladder, commonly in a physician's office.Type: ApplicationFiled: April 29, 2008Publication date: November 6, 2008Inventor: Jeffrey A. Potter
-
Publication number: 20080262229Abstract: Compounds of formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.Type: ApplicationFiled: February 24, 2006Publication date: October 23, 2008Applicant: ASTRAZENECA ABInventors: William Brown, Andrew Griffin, Andrea Penwell
-
Publication number: 20080261985Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: ApplicationFiled: November 16, 2007Publication date: October 23, 2008Inventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby
-
Publication number: 20080241237Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.Type: ApplicationFiled: March 27, 2008Publication date: October 2, 2008Inventor: Gopi Venkatesh
-
Publication number: 20080214572Abstract: This invention concerns novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof, and a quaternary ammonium salt thereof, wherein all substituents are defined as in claim 1.Type: ApplicationFiled: May 17, 2006Publication date: September 4, 2008Inventors: Francisco Javier Fernandez-Gadea, Jose Ignacio Andres-Gil, Andres Avelino Trabanco-Suarez, Jose Maria Cid-Nunez, Antonius Adrianus Hendrikus Petrus Megens
-
Publication number: 20080207530Abstract: The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.Type: ApplicationFiled: February 12, 2008Publication date: August 28, 2008Inventors: Michalis Nicolaou, Emile Loria, Gaetan Terrasse, Yves Trehin
-
Publication number: 20080207593Abstract: A once daily formulation containing the combination of a non-sedating or selective antihistamine (Loratadine) with a sedating or non-selective antihistamine (Chlorpheniramine) administered at bed-time has demonstrated greater efficacy in relieving allergic symptoms than Loratadine alone.Type: ApplicationFiled: August 20, 2007Publication date: August 28, 2008Inventors: Michael Heffernan, Jane C. Hirsh, Roman V. Rariy
-
Publication number: 20080206331Abstract: The present invention concerns a tablet comprising two distinct segments. More particularly the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.Type: ApplicationFiled: June 14, 2007Publication date: August 28, 2008Applicant: UCB, S.A.Inventors: Monique Berwaer, Anthony Guichaux, Serge Cuypers, Michel Deleers, Domenico Fanara
-
Publication number: 20080200848Abstract: The present invention discloses a method of treating nasal congestion and/or relieving sinusitis symptoms in a patient comprising attaching a vibration generating means to the patient head, at a location adjacent to sinuses to be treated, generating a vibration by said vibration generating means, and delivering the same to said patient. The present invention also discloses a device for treating nasal congestion and/or relieving sinusitis symptoms in a patient, comprising attaching means and a vibration generating means; said attaching means are in communication with the patient's head in a location adjacent to said nasal cavity, nasal passageway or sinuses to be treated; said generating means are adapted to vibrate said attaching means, to vibrate the location adjacent to said nasal cavity or sinuses and thus improved mucociliary clearance of secretions in nasal cavity or sinuses.Type: ApplicationFiled: May 24, 2006Publication date: August 21, 2008Applicant: ADS & B INVESTMENT FUND L.PInventor: Yuval Avni
-
Patent number: 7396834Abstract: Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.Type: GrantFiled: November 5, 2003Date of Patent: July 8, 2008Assignee: AstraZeneca ABInventors: William Brown, Andrew Griffin, Niklas Plobeck, Christopher Walpole
-
Patent number: 7384929Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl or heteroaryl azaspiroalkene/alkane compounds, prodrugs or metabolites of these compounds, or pharmaceutically acceptable salts thereof. The aryl group can be a phenyl ring or a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic cholinergic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain.Type: GrantFiled: September 19, 2005Date of Patent: June 10, 2008Assignee: Targacept, Inc.Inventors: Balwinder Bhatti, Scott R. Breining, Philip S. Hammond, Jozef Klucik, Yun-De Xiao
-
Publication number: 20080125443Abstract: The present invention relates to compositions and methods of treatment for cardioprotection through the use of non-peptidic delta opioid receptor agonist compound(s) that mediate cardioprotective effects of ischemic preconditioning. The compounds are used to reduce injury associated with ischemia and reperfusion of cardiac tissue. Further, the compounds may be used in solutions preserving the viability of an isolated organ.Type: ApplicationFiled: November 27, 2007Publication date: May 29, 2008Inventors: Kwen-Jen Chang, William Pendergast, Peter J. Gengo, Xin Ma
-
Publication number: 20080119487Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.Type: ApplicationFiled: November 20, 2007Publication date: May 22, 2008Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
-
Patent number: 7375106Abstract: The invention relates to a combined pharmaceutical preparation comprising an opioid diarylmethyl piperazine compounds and a NSAID. Such a preparation in which the compounds are either given sequentially or simultaneously can be used for the treatment of pain diminishing the side-effects observed in conventional opioid treatments.Type: GrantFiled: May 12, 2003Date of Patent: May 20, 2008Assignee: N.V. OrganonInventors: Andrea Houghton, Jean Cottney
-
Publication number: 20080014274Abstract: An oral, liquid pharmaceutical composition is provided. The composition comprises phenylephrine and substantially aldehyde-free polyethylene glycol. The composition has phenylephrine stability compatible with the stability required for commercial preparations. Optionally, the composition may comprise one or more additional active agents.Type: ApplicationFiled: July 14, 2006Publication date: January 17, 2008Applicant: WyethInventors: William Bubnis, Stephanie Shield, Gayle P. Hoskovec
-
Patent number: 7314880Abstract: The present invention relates to compositions and methods of treatment for cardioprotection through the use of non-peptidic delta opioid receptor agonist compound(s) that mediate cardioprotective effects of ischemic preconditioning. The compounds are used to reduce injury associated with ischemia and reperfusion of cardiac tissue. Further, the compounds may be used in solutions preserving the viability of an isolated organ.Type: GrantFiled: December 31, 2003Date of Patent: January 1, 2008Assignee: Mount Cook Biosciences, Inc.Inventors: Kwen-Jen Chang, William Pendergast, Peter J. Gengo, Xin Ma
-
Publication number: 20070297990Abstract: The invention provides self-preserving compositions and methods for their production.Type: ApplicationFiled: June 27, 2006Publication date: December 27, 2007Inventors: Mandar V. Shah, Uday Doshi, Ken T. Holeva
-
Patent number: 7253173Abstract: Compounds of general formula (I) wherein R1, R2 and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared.Type: GrantFiled: November 5, 2003Date of Patent: August 7, 2007Assignee: AstraZeneca ABInventors: William Brown, Andrew Griffin, Paul Jones, Daniel Pagé, Niklas Plobeck, Christopher Walpole
-
Patent number: 7241764Abstract: Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared.Type: GrantFiled: November 5, 2003Date of Patent: July 10, 2007Assignee: AstraZeneca ABInventors: William Brown, Andrew Griffin
-
Patent number: 7241801Abstract: A compound, represented by formula (I): wherein A, B, R1, R2, R3, R5, R6, R7, R9, and R10 are as defined herein, or an enantiomer, diastereoisomer or tautomer thereof, including a salt, ester or derivative thereof, as an inhibitor of HCV NS5B polymerase.Type: GrantFiled: July 15, 2005Date of Patent: July 10, 2007Assignee: Boehringer Ingelheim International GmbHInventors: Pierre Beaulieu, Christian Brochu, Stephen Kawai, Jean Rancourt, Timothy A. Stammers, Bounkham Thavonekham, Youla S. Tsantrizos
-
Patent number: 7229994Abstract: Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, and pyridine N-oxide; R2 is independently selected from ethyl and isopropyl; R3 is independently selected from hydrogen and fluoro; R4 is independently selected from —OH, —NH2 and —NHSO2R5; and R5 is independently selected from hydrogen, —CF3 and C1–C6 alkyl, or salts thereof or separate enantiomers and salts thereof; where each R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1–C6 alkyl, NO2, CF3, C1–C6 alkoxy, chloro, fluoro, bromo, and iodo.Type: GrantFiled: May 16, 2002Date of Patent: June 12, 2007Assignee: AstraZeneca ABInventors: William Brown, Christopher Walpole, Niklas Plobeck
-
Patent number: 7141573Abstract: One aspect of the present invention relates to polypharmacophoric compounds. In certain embodiments, the polyphamacophore compounds comprise individual pharmacophore units selected from the group consisting of D-1 agonists, D-2 agonists, D-3 agonists, D-4 agonists, irreversible monoamine inhibitors, reversible monoamine inhibitors, monoamine transporter inhibitors, COMT inhibitors, MAO inhibitors, and dopamine transporter inhibitors. Moreover, the present invention also relates to combinatorial libraries of polypharmacophoric compounds. Another aspect of the present invention relates to the use of a polypharmacophoric compound in a method of treating a mammal in need thereof. For example, a polypharmacophoric compound of the present invention may be used in a method of treating a mammal afflicted with Alzheimer's Disease, Huntington's Disease, depression, attention deficit disorder, autism, obesity, or inflammation.Type: GrantFiled: January 11, 2001Date of Patent: November 28, 2006Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: Robert N. Hanson, John W. Babich
-
Patent number: 7135473Abstract: A cyclic diamine compound of formula (1): wherein R1 and R2 are individually a hydrogen atom or a methoxy group, provided R1 is a methoxy group when R2 is a hydrogen atom, or a hydrogen atom when R2 is a methoxy group; A is an oxygen atom, a sulfur atom, CH?CH, CH?N or NR3, in which R3 is a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; B is a nitrogen atom, CH or CR4, in which R4 is a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; m is 1 or 2; and n is a number of 1 to 5, an acid-addition salt thereof, or a hydrate thereof. The compound has inhibitory effects on cell adhesion and is useful for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation.Type: GrantFiled: August 13, 2003Date of Patent: November 14, 2006Assignee: Kowa Co., Ltd.Inventors: Tatsuhiko Kodama, Masahiro Tamura, Toshiaki Oda, Yukiyoshi Yamazaki, Masahiro Nishikawa, Takeshi Doi, Yoshinori Kyotani
-
Patent number: 7101572Abstract: A substantially taste masked liquid pharmaceutical composition containing a pharmaceutically effective amount of an unpleasant tasting drug dissolved or dispersed in an aqueous excipient base, said excipient base comprising polyvinyl pyrrolidone and/or copolyvidone, and high molecular weight polyethylene glycol.Type: GrantFiled: December 7, 2001Date of Patent: September 5, 2006Assignee: Unilab Pharmatech, Ltd.Inventors: Joyce Bedelia B. Santos, Rita Josefina M. Santos, Kennie U. Dee